Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
boston top stories
life sciences
medical devices
8
×
national blog main
national top stories
8
×
san francisco blog main
san francisco top stories
biotech
detroit blog main
detroit top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
fda
indiana blog main
indiana top stories
national
novartis
cancer
deals
investing
startups
abbvie
biofourmis
crispr
eli lilly
glaxosmithkline
What
bio
roundup
life
big
biofourmis
companies
days
develop
devices
drugs
mammoth
new
patients
science
startup
therapeutics
abbvie’s
admits
advantages
ago
ahead
analytics
august
available
bails
bar
based
biosciences
biotech
biotechs
black
brand
bridgebio
brings
bucks
busy
cancer
capital
car
cas
Language
unset
8
×
Current search:
photo
×
" national top stories "
×
" medical devices "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More